FDA permits trial of Omeros drug for thrombotic microangiopathies

04/3/2014 | FDAnews

Omeros obtained the FDA's approval to initiate a midstage trial of its monoclonal antibody candidate OMS721 in patients with complement-mediated thrombotic microangiopathies. The trial, which will test the safety and efficacy of the drug, is scheduled to start this quarter.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ